Antiviral specialist Gilead Sciences (Nasdaq: GILD) has announced a new approval from the US Food and Drug Administration, for Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide).
The agency has given its blessing for marketing of the product to treat people with HIV who have suppressed viral loads, with a particular form of treatment resistance.
With peak revenues for its blockbuster hepatitis C portfolio now in the past, Gilead has successfully developed growth momentum for Biktarvy, a once-daily triplet med with a high barrier to resistance.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze